Top-Rated StocksTop-RatedNASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Forecast, Price & News $16.40 -0.16 (-0.97%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$16.01▼$17.0050-Day Range$14.58▼$20.1552-Week Range$14.47▼$36.64Volume555,261 shsAverage Volume805,271 shsMarket Capitalization$981.21 millionP/E RatioN/ADividend YieldN/APrice Target$48.55 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Pliant Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside196.0% Upside$48.55 Price TargetShort InterestBearish10.55% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment0.65Based on 16 Articles This WeekInsider TradingSelling Shares$2.60 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.99) to ($3.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector263rd out of 969 stocksPharmaceutical Preparations Industry104th out of 455 stocks 4.5 Analyst's Opinion Consensus RatingPliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.55, Pliant Therapeutics has a forecasted upside of 196.0% from its current price of $16.40.Amount of Analyst CoveragePliant Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.55% of the outstanding shares of Pliant Therapeutics have been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 4.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Pliant Therapeutics is -0.73. Previous Next 2.0 News and Social Media Coverage News SentimentPliant Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,596,440.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pliant Therapeutics is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pliant Therapeutics is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pliant Therapeutics (NASDAQ:PLRX) StockPliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More PLRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLRX Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comPliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?September 27, 2023 | finance.yahoo.comPliant (PLRX) Up on Success of Mid-Stage Liver Disease StudySeptember 28, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 27, 2023 | markets.businessinsider.comPromising Interim Results from Pliant Therapeutics’ INTEGRIS-PSC Study Bolster Buy RatingSeptember 26, 2023 | markets.businessinsider.comPliant Therapeutics Reveals Encouraging Data From Liver Disease TrialSeptember 26, 2023 | markets.businessinsider.comPliant Therapeutics: Bexotegrast INTEGRIS-PSC Interim Data Surpasses ExpectationsSeptember 26, 2023 | msn.comPliant Therapeutics' Multi-Pronged Fibrosis PlaySeptember 26, 2023 | finance.yahoo.comWhy Shares of Pliant Therapeutics Are Rising TuesdaySeptember 28, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 26, 2023 | finance.yahoo.comRebel's Edge - September 26: $IMVT, $PLRX, $UNFI, and The PAC12September 26, 2023 | finance.yahoo.comPliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver FibrosisSeptember 25, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Pliant Therapeutics (PLRX), Simulations Plus (SLP)September 25, 2023 | finance.yahoo.comPliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing CholangitisSeptember 24, 2023 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Shares Down 4.7% September 15, 2023 | finance.yahoo.comPliant Therapeutics Appoints Minnie Kuo as Chief Development OfficerSeptember 15, 2023 | seekingalpha.comIn Therapeutics Space, I Prefer Vicore Pharma Over Pliant TherapeuticsSeptember 12, 2023 | markets.businessinsider.comPliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023September 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Liquidia Technologies (LQDA) and Arcus Biosciences (RCUS)August 29, 2023 | finance.yahoo.comPliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023August 28, 2023 | finance.yahoo.comPliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023August 22, 2023 | msn.comCantor Fitzgerald Reiterates Pliant Therapeutics (PLRX) Overweight RecommendationAugust 18, 2023 | finanznachrichten.dePliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsAugust 14, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Pliant Therapeutics (PLRX)August 11, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX), Lineage Therap (LCTX) and Harpoon Therapeutics (HARP)August 11, 2023 | seekingalpha.comPliant Therapeutics: Promising Phase 2a Bexotegrast Data UnveiledAugust 9, 2023 | finance.yahoo.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial ResultsSee More Headlines Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PLRX Company Calendar Last Earnings8/09/2023Today9/28/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PLRX CUSIPN/A CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Forecast$48.55 High Stock Price Forecast$63.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+199.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,320,000.00 Net Margins-2,872.79% Pretax Margin-2,872.79% Return on Equity-33.10% Return on Assets-30.39% Debt Debt-to-Equity Ratio0.02 Current Ratio19.16 Quick Ratio19.16 Sales & Book Value Annual Sales$9.69 million Price / Sales100.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.43 per share Price / Book2.52Miscellaneous Outstanding Shares59,830,000Free Float56,483,000Market Cap$970.44 million OptionableNot Optionable Beta1.25 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Bernard Coulie M.B.A. (Age 57)M.D., MBA, Ph.D., Pres, CEO & Director Comp: $1.06MDr. Keith Lamont Cummings M.B.A. (Age 46)M.D., Chief Financial Officer Comp: $662.34kMr. Mike Ouimette J.D. (Age 50)Gen. Counsel & Corp. Sec. Comp: $591.05kMr. Johannes P. Hull (Age 48)Chief Bus. Officer Comp: $631.64kDr. Éric Lefebvre M.D. (Age 59)Chief Medical Officer Comp: $763.49kDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Craig D. MuirInterim Chief Technology OfficerMore ExecutivesKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLDeciphera PharmaceuticalsNASDAQ:DCPHMorphicNASDAQ:MORFKeros TherapeuticsNASDAQ:KROSLigand PharmaceuticalsNASDAQ:LGNDView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 20,076 shares on 8/21/2023Ownership: 0.096%Osaic Holdings Inc.Bought 1,331 shares on 8/21/2023Ownership: 0.005%Nuveen Asset Management LLCBought 160,728 shares on 8/16/2023Ownership: 0.349%Walleye Capital LLCSold 2,200 shares on 8/15/2023Ownership: 0.000%Walleye Trading LLCSold 2,600 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PLRX Stock - Frequently Asked Questions Should I buy or sell Pliant Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLRX shares. View PLRX analyst ratings or view top-rated stocks. What is Pliant Therapeutics' stock price forecast for 2023? 11 brokerages have issued 1 year price targets for Pliant Therapeutics' shares. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they anticipate the company's share price to reach $48.55 in the next twelve months. This suggests a possible upside of 199.3% from the stock's current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts. How have PLRX shares performed in 2023? Pliant Therapeutics' stock was trading at $19.33 at the start of the year. Since then, PLRX shares have decreased by 16.1% and is now trading at $16.22. View the best growth stocks for 2023 here. When is Pliant Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our PLRX earnings forecast. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.03. The firm earned $0.25 million during the quarter, compared to analysts' expectations of $1.10 million. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative trailing twelve-month return on equity of 33.10%. What ETFs hold Pliant Therapeutics' stock? ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). When did Pliant Therapeutics IPO? (PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. What is Pliant Therapeutics' stock symbol? Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX." Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.45%), Deep Track Capital LP (6.77%), Casdin Capital LLC (2.84%), Polar Capital Holdings Plc (2.74%), Great Point Partners LLC (2.59%) and Franklin Resources Inc. (2.54%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pliant Therapeutics' stock price today? One share of PLRX stock can currently be purchased for approximately $16.22. How much money does Pliant Therapeutics make? Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $970.44 million and generates $9.69 million in revenue each year. The company earns $-123,320,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. How many employees does Pliant Therapeutics have? The company employs 155 workers across the globe. How can I contact Pliant Therapeutics? Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com. This page (NASDAQ:PLRX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.